Key points are not available for this paper at this time.
Population
Patients with a reduced ejection fraction, a widened QRS complex, and NYHA class II or III heart failure
Comparison
CRT-D vs ICD
Follow-up
Median of nearly 14 years
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“With CRT-D, we observed an approximately 20% reduction in the rate of death, which persisted through [14 years] of observation.”
May inform CRT-D selection in eligible HF patients; extends RAFT observations yet remains observational.
Among patients with a reduced ejection fraction, a widened QRS complex, and NYHA class II or III heart failure, the survival benefit associated with receipt of a CRT-D as compared with ICD appeared to be sustained during a median of nearly 14 years of follow-up. (RAFT ClinicalTrials.gov number, NCT00251251.).
No takes yet. Share an insight, caveat, or question.
Sapp et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: